MannKind Corporation  

(Public, NASDAQ:MNKD)   Watch this stock  
Find more results for mnkd
-0.012 (-1.16%)
Real-time:   3:10PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.98 - 1.02
52 week 0.64 - 5.37
Open 1.00
Vol / Avg. 1.41M/3.77M
Mkt cap 475.86M
P/E     -
Div/yield     -
EPS -0.87
Shares 477.68M
Beta 1.76
Inst. own 19%
Aug 8, 2016
Q2 2016 MannKind Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 12, 2016
MannKind Corp at Cantor Fitzgerald Healthcare Conference - Webcast
May 20, 2016
Mannkind Corp Annual Shareholders Meeting (Estimated)
May 19, 2016
Mannkind Corp Annual Shareholders Meeting
May 12, 2016
MannKind Corp at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Mannkind Corp Earnings Call
May 9, 2016
Q1 2016 Mannkind Corp Earnings Release
Apr 26, 2016
Mannkind Corp to Discuss U.S. Commercialization Update of Afrezza Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -90.83% -141.48%
Return on average equity - -
Employees 192 -
CDP Score - -


25134 Rye Canyon Loop Ste 300
VALENCIA, CA 91355-5031
United States - Map
+1-661-7755300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Officers and directors

Kent Kresa Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Matthew Jonathan Pfeffer Chief Executive Officer, Chief Financial Officer, Director
Age: 57
Bio & Compensation  - Reuters
Rose Alinaya Chief Accounting Officer
Age: 54
Bio & Compensation  - Reuters
David B. Thomson Ph.D., J.D. Corporate Vice President, General Counsel, Corporate Secretary
Age: 48
Bio & Compensation  - Reuters
Diane M. Palumbo Corporate Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael E. Castagna Chief Commercial Officer
Bio & Compensation  - Reuters
James S. Shannon M.D. Director
Age: 57
Bio & Compensation  - Reuters
Ronald J. Consiglio Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael A. Friedman M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
David H. MacCallum Independent Director
Age: 77
Bio & Compensation  - Reuters